Creo Medical Group Plc · LSE:CREO
Creo Medical — Cenkos Securities / Proactive Investor Virtual Growth and Innovation Forum 2022
18 slides from Creo Medical's conference presentation, Feb 8, 2022
Slide 1: Bringing Advanced Energy to Endoscopy
BRINGING ADVANCED ENERGY TO ENDOSCOPY Cenkos Securities / Proactive Investor Virtual Growth and Innovation Forum 8th February 2022 Prof. Christopher Hancock, Founder and CTO, Creo Medical Group plc (AIM:CREO)
Slide 2: Disclaimer
Disclaimer IMPORTANT NOTICE This presentation comprises the written materials/slides (“presentation”) concerning Creo Medical Group PLC (the “Company”) and technologies and/or products developed or under development by the Company. By reviewing this presentation you agree to be bound by the followin
Slide 3: Creo Medical at a glance (AIM:CREO)
Creo Medical at a glance (AIM:CREO) • Creo Medical is an Advanced Energy company focussed on the development and commercialisation of minimally invasive electrosurgical devices – Bringing Advanced Energy To Endoscopy. • Over 290 employees in 8 countries. 2016 IPO • Experienced management team, with
Slide 4: Quick Procedure Comparison
Quick Procedure Comparison Less Invasive, Less Complications, Lower Healthcare Costs, Better Patient Experience Surgery Laparoscopy Endoscopy • Invasive with large incisions • Less-invasive surgery utilising • Non-invasive surgery utilising performed in operating rooms small incisions to penetrate t
Slide 5: Global Reach, Global Markets (December 2021)
Global Reach, Global Markets (December 2021) 150 R&D/Ops 20 USA 4,800 + 8 Direct UK (x5) USA 22 22 signed 290 80 S&M 260 EMEA Countries Ger, Fra, Spain Hong Kong Countries 10 + in negotiation Hospital, Doctor & People Clinic Customers Indirect 60 G&A 10 APAC 12 Offices Bel/Lux Singapore EMEA & APAC
Slide 6: Build
KW cc... Build with the right approach
Slide 7: Creo Medical Device Portfolio
Creo Medical Device Portfolio powered by Kamaptive™ Technology Energy Platform Gastrointestinal Lesions General / (including Bowel and Upper GI Soft tissue Cutting Gastrointestinal cancer) ablation & Swallowing Disorders Bleeding Speedboat™ SpydrBlade™ SlypSeal™ MicroBlate™ Technology Technology Tec
Slide 8: Speedboat
Speedboat™ Speedboat Inject and Speedboat Submucosal Dissection (SSD), allows more physicians to be comfortable adopting advanced endoscopic techniques that will reduce the recurrence of cancer, lower healthcare costs and improve patient experience. Market Overview Activities 2021 Opportunity • ~28M
Slide 9: SSD Patient Experience
SSD Patient Experience 10cm lesion removed via Speedboat Submucosal Dissection 14.5cm lesion removed via Speedboat Submucosal Dissection “I just feel that I'm back to normal, completely. I'm not quite sure where I would “It seemed like a very obvious solution…like a definite way forward. And have be
Slide 10: Highlighting Speedboat Adoption in the Market
Highlighting Speedboat Adoption in the Market Follow us on Twitter & LinkedIn @CreoEndoscopy and @CreoMedical 10
Slide 11: UK Savings
UK Savings Clinical Impact & Health Economic Data Cumulative Savings ▪ Alternative is for up to 30cm of bowel removed and the two sections rejoined 2018 ~£0.3m ▪ Potential stoma bag for up to 6 months or even life 2019 ~£1m ▪ Other associated effects such as depression £2,500,000 2020 ~£1.6m ▪ Betwe
Slide 12: MicroBlate Fine Treats First Pancreatic Tumours
MicroBlate™ Fine Treats First Pancreatic Tumours MicroBlate Fine Microwave Ablation (MWA) of NET Tumour EUS Guided MWA CT Scan 2 Months Post Ablation Carlos Robles Medranda - Global KOL and trainer MicroBlate Fine Homogeneous tissue after • Recognised international KOL provide fast validation and pr
Slide 13: Partner
KW cc... Partner
Slide 14: Kamaptive Technology
Kamaptive Technology Seamless, intuitive integration of multi-modal energy sources, optimised to adapt to tissue to improve patient outcomes Wide spectrum multi-modal Closed loop multi-modal Automatic device Simultaneous delivery Bipolar advanced energy used from real time tissue feedback recognitio
Slide 15: Kamaptive Partner Opportunities
Kamaptive Partner Opportunities Partner 1 Partner 2 Partner 3 Initial Discussions / NDA Concept Definition / Compatibility Proof of Concept Heads of Terms Signed Signed Signed Signed Agreement 2022 2022 2022 Robotic Surgery predominantly Plasma Sterilisation limited to: Creo has successfully demonst
Slide 16: Summary
KW cc... Summary
Slide 17: Conclusion
Conclusion 2022 focus for Creo is to accelerate commercialisation in US, EMEA and APAC, develop the Kamaptive potential specifically in Robotics, continue R&D and pursue M&A opportunities where appropriate • Creo’s CROMA Advanced Energy platform powered by Kamaptive and product development enables a
Slide 18: Anything is possible with the right approach
KW ce... Anything is possible with the right approach